Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906448 · ClinicalTrials.gov registry record · Phase 2
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03906448 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 1 participants.
The verdict
NCT03906448, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone in historical controls after the completion of definitive chemoradiotherapy. Study treatment may continue past first tumor recurrence. The primary endpoint will be overall survival.
Interventions
- COMBINATION_PRODUCT TTFields with adjuvant temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2020-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03906448
The ClinicalTrials.gov registry entry for NCT03906448 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TTFields with adjuvant temozolomide is the first listed.
NCT03906448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03906448 about?
NCT03906448 is a clinical study titled "FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma". This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone in historical controls after the completion of definitive chemoradiother...
What is the current status of trial NCT03906448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-05-20. Estimated completion is 2020-06-08.
What interventions are being tested in trial NCT03906448?
The interventions under investigation include: TTFields with adjuvant temozolomide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03906448?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.